63236-23-7
63236-23-7 structure
- Name: Pareptide monohydrochloride
- Chemical Name: Pareptide monohydrochloride
- CAS Number: 63236-23-7
- Molecular Formula: C14H27ClN4O3
- Molecular Weight: 334.842
- Catalog: Research Areas Neurological Disease
- Create Date: 2018-01-06 03:55:16
- Modify Date: 2024-01-12 12:37:58
-
Pareptide monohydrochloride is a melanotropin-inhibiting factor (MIF) metabolically stable analogue.
| Name | Pareptide monohydrochloride |
|---|---|
| Synonyms |
L-Prolyl-N-methylleucylglycinamide hydrochloride (1:1)
Glycinamide, L-prolyl-N-methylleucyl-, hydrochloride (1:1) GC65JE8O95 PAREPTIDE HYDROCHLORIDE |
| Description | Pareptide monohydrochloride is a melanotropin-inhibiting factor (MIF) metabolically stable analogue. |
|---|---|
| Related Catalog | |
| In Vivo | Chronic coadministration of Pareptide (0.25 mg/kg, SC, BID, 3.5 days) to mice pretreated with Haloperidol (8.0 mg/kg, IP, BID, 3 days) significantly increases the cataleptic effects of a smaller challenge dose of Haloperidol (2.0 mg/kg, IP) given 15 hours after the last pretreatment injections (p<0.01)[1]. |
| Animal Admin | Mice[1] Male albino mice of a Swiss-Webster derived strain and eighing from 26-34 g are used. Single doses of MIF-I (0.03-2.0 mg/kg, SC) and chronic pretreatments with MIF-I (0,03-2.0 mg/kg, SC, BID, 3.5 days) or Pareptide (0.25 mg/kg, SC, BID, 3.5 days) do not affect the acute cataleptic response to Haloperidol in the mouse. Pareptide is given SC in a 5 mL/kg injection volume. Chronic pretreatment with Haloperidol (8.0 mg/kg, IP, BID, 3 days) decreases the duration of catalepsy in mice given smaller challenge doses of Haloperidol (2.0 or 3.0 mg/kg, IP) 15 hours after the last pretreatment injections. Administration of either MIF-I or Pareptide to mice also chronically pretreated with Haloperidol antagonizes the development of tolerance[1]. |
| References |
| Molecular Formula | C14H27ClN4O3 |
|---|---|
| Molecular Weight | 334.842 |
| Exact Mass | 334.177155 |